<DOC>
	<DOC>NCT00909506</DOC>
	<brief_summary>The investigators hypothesize that adjuvant metformin use in breast cancer patients with overweight or pre-diabetes mellitus (DM) may improve their body condition including weight loss. In this study, the investigators aim to test the efficacy and safety of adjuvant metformin for operable breast cancer patients with overweight or pre-DM.</brief_summary>
	<brief_title>Efficacy and Safety of Adjuvant Metformin for Operable Breast Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Operable Breast cancer patients with BMI ≥ 23 or 100 ≤ FBS &lt; 126 From 6 month to 2 years since breast cancer operation and at least 4 weeks since chemotherapy or radiotherapy No drug use except Tamoxifen Normal OTPT &amp; Serum creatinine (&lt;=ULN) ECOG performance status 02 or Karnofsky PS 60100% Life expectancy &gt; 12 Absolute neutrophil count ≥ 1.5 x 10^9/L Platelets ≥ 100 x 10^9/L Pregnancy() &amp; without plan for pregnancy Sign a written informed consent form Type I or II DM or concurrent use of DM control agents Prior use of Metformin Hypoglycemia (FBS&lt; 70 with clinical symptom) Concurrent investigational or commercial agents Other diet or drug intervention for weight loss Concurrent use of steroid Abnormal liver and/or renal function Symptomatic congestive heart failure / Cardiac arrhythmia / Angina pectoris Ongoing or active infection lactic acidosis Pregnancy or ongoing breast feeding Anorexia, bulimia, nausea due to other disease for longer than 1 month Allergies or allergic reactions attributed to oral medications Inability to swallow or digest oral medications Physical or psychiatric illness that would limit compliance with study protocol Participants in other clinical trial</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
</DOC>